Free Trial
OTCMKTS:DSNKY

Daiichi Sankyo (DSNKY) Stock Price, News & Analysis

Daiichi Sankyo logo
$25.20 +0.25 (+0.98%)
As of 03:50 PM Eastern

About Daiichi Sankyo Stock (OTCMKTS:DSNKY)

Key Stats

Today's Range
$25.12
$25.69
50-Day Range
$21.84
$27.22
52-Week Range
$20.92
$42.48
Volume
82,612 shs
Average Volume
266,183 shs
Market Capitalization
$48.08 billion
P/E Ratio
29.30
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Strong Buy

Company Overview

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

Receive DSNKY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Daiichi Sankyo and its competitors with MarketBeat's FREE daily newsletter.

DSNKY Stock News Headlines

Get Ready for Elon Musk’s BIGGEST Comeback Yet
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
DSKYF Daiichi Sankyo Company, Limited
See More Headlines

DSNKY Stock Analysis - Frequently Asked Questions

Daiichi Sankyo's stock was trading at $27.29 at the beginning of the year. Since then, DSNKY shares have decreased by 7.7% and is now trading at $25.1950.
View the best growth stocks for 2025 here
.

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) posted its quarterly earnings data on Friday, April, 25th. The company reported $0.30 earnings per share (EPS) for the quarter. The business had revenue of $3.40 billion for the quarter. Daiichi Sankyo had a trailing twelve-month return on equity of 14.53% and a net margin of 13.62%.

Shares of DSNKY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
4/25/2025
Today
6/12/2025
Next Earnings (Estimated)
7/29/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:DSNKY
Previous Symbol
OTCMKTS:DSNKY
CIK
N/A
Fax
N/A
Employees
17,435
Year Founded
N/A

Profitability

Trailing P/E Ratio
29.01
Forward P/E Ratio
34.18
P/E Growth
1.72
Net Income
$1.39 billion
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$11.09 billion
Price / Cash Flow
N/A
Book Value
$5.62 per share
Price / Book
4.44

Miscellaneous

Outstanding Shares
1,908,322,000
Free Float
N/A
Market Cap
$47.61 billion
Optionable
Not Optionable
Beta
N/A
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (OTCMKTS:DSNKY) was last updated on 6/12/2025 by MarketBeat.com Staff
From Our Partners